Summary
Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics.
The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics development and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
Scope
- The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)
- The report reviews Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics and enlists all their major and minor projects
- The report assesses Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
AbbVie Inc
Handok Inc
XBiotech Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview 6
Therapeutics Development 7
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Stage of Development 7
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Therapy Area 8
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Indication 9
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Companies 12
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Companies Involved in Therapeutics Development 20
AbbVie Inc 20
Handok Inc 21
XBiotech Inc 22
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Drug Profiles 23
ABT-981 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
CV-18C3 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
HL-2351 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
RA-18C3 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
T-218C3 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Xilonix - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Dormant Projects 35
Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Featured News & Press Releases 36
Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer 36
Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection 36
Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU 37
Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer 37
Jul 02, 2016: XBiotech Presents Pivotal Phase III Data Showing Xilonix Demonstrated Significant Clinical Response in Advanced Colorectal Cancer Patients Refractory to Further Treatment 39
Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio 40
May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer 41
Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer 41
Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech’s True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer 42
Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer 43
Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency 43
Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech’s Marketing Authorization Application 44
Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament 45
Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium 45
Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49
List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by AbbVie Inc, H2 2016 20
Pipeline by Handok Inc, H2 2016 21
Pipeline by XBiotech Inc, H2 2016 22
Dormant Projects, H2 2016 35
List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Routes of Administration, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Molecule Types, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 18
